Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Capital Expenditures (2018 - 2025)

UroGen Pharma's Capital Expenditures history spans 8 years, with the latest figure at $17000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 85.22% year-over-year to $17000.0; the TTM value through Dec 2025 reached $289000.0, down 2.03%, while the annual FY2025 figure was $289000.0, 2.03% down from the prior year.
  • Capital Expenditures reached $17000.0 in Q4 2025 per URGN's latest filing, down from $87000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $287000.0 in Q1 2021 to a low of $13000.0 in Q4 2022.
  • Average Capital Expenditures over 5 years is $93894.7, with a median of $84000.0 recorded in 2024.
  • Peak YoY movement for Capital Expenditures: plummeted 93.56% in 2022, then soared 460.0% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $202000.0 in 2021, then tumbled by 93.56% to $13000.0 in 2022, then surged by 330.77% to $56000.0 in 2023, then skyrocketed by 105.36% to $115000.0 in 2024, then plummeted by 85.22% to $17000.0 in 2025.
  • Per Business Quant, the three most recent readings for URGN's Capital Expenditures are $17000.0 (Q4 2025), $87000.0 (Q3 2025), and $141000.0 (Q2 2025).